echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > 75% objective relief!

    75% objective relief!

    • Last Update: 2022-01-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 6, 2021, Adicet Bio announced that a dose-escalation phase 1 clinical trial of the allogeneic, "ready-to-use" CD20 targeting CAR γδ-T cell therapy ADI-001 has obtained positive interim data


    γδ-T cells are part of the human innate immune system.


    The trial plans to enroll approximately 75 patients with refractory/relapsed B-cell non-Hodgkin lymphoma


    In terms of safety, ADI-001 showed good tolerance


    The specific results of the test are shown in the following table:

    Table source: Reference materials[1]

    Reference materials:

    [1] Adicet Bio Announces Positive Interim Clinical Data From First-Ever Allogeneic, Off-The-Shelf, Gamma Delta CAR T Investigational Cell Therapy.


    (The original text has been deleted)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.